


	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELTRA.009A	APPLICATION NO. 09/741,869
	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT Forsyth, et al.
	(USE SEVERAL SHEETS IF NECESSARY)			FILING DATE December 19, 2000

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Branch, A. D. 1998. A good antisense molecule is hard to find. <i>TIBS</i> , 23:45-50.
	2	Dove, A. 2002. Antisense and sensibility. <i>Nature Biotechnology</i> , 20:121-124.
	3	Gucev, et al. 1999. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β 2-induced growth inhibition in human breast cancer cells. <i>Cancer Research</i> , 59(7):1545-1550.
	4	Lebedeva, et al. 2001. Antisense oligonucleotides: Promise and reality. <i>Annu. Rev. Pharmacol. Toxicol.</i> , 41:403-419.
	5	Sofia, et al. "Analysis of the <i>Escherichia coli</i> genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Database accession no. XP-002228918.

S:\DOCS\DOH\DOH-7344.DOC:dmb
031703

EXAMINER		DATE CONSIDERED	12/31/2003
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			